MetaCap

Enanta Pharmaceuticals (ENTA) vs Immuneering (IMRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enanta Pharmaceuticals (ENTA) has outperformed Immuneering (IMRX) over the past year, losing 40.1% versus a loss of 53.7%. Over five years, IMRX leads with a -85.0% price change compared with -91.7% for ENTA. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $218.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENTA-40.14%IMRX-53.70%
+37%-11%-58%
Nov 21, 20251 yearNov 20, 2026
ENTA-89.88%IMRX-86.40%
+28%-37%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENTA versus IMRX key metrics
MetricENTAIMRX
Share price$7.62$3.38
Market cap$222.19M$218.90M
1-day change-4.51%-2.03%
YTD return-51.68%-48.63%
1-year return-40.14%-53.70%
5-year return-91.71%-85.00%
EPS (TTM)$-2.35$-0.92
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$63.00M—
Revenue growth (YoY)-3.56%—
Net income (latest FY)$-68.25M$-56.02M
Operating margin-99.01%—
Net margin-108.33%—
52-week high$17.15$8.48
52-week low$7.56$3.29
Distance from 52-week high-55.57%-60.14%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+186.48%+402.96%
Average volume287.81K747.66K
Shares outstanding29.16M64.76M
Employees12065
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ENTA has outperformed IMRX by 13.6 percentage points over the past year.

About Enanta Pharmaceuticals

ENTA stock →

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

About Immuneering

IMRX stock →

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

ENTA vs IMRX FAQ

Which is bigger, Enanta Pharmaceuticals or Immuneering?

Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $218.90M for Immuneering (IMRX).

Which stock has performed better over the past year, ENTA or IMRX?

ENTA returned -40.14% over the past 12 months, compared with -53.70% for IMRX (price return, excluding dividends). Past performance does not predict future results.

Are Enanta Pharmaceuticals and Immuneering in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons